Literature DB >> 11811929

Chronic beryllium disease: a model interaction between innate and acquired immunity.

Richard T Sawyer1, Lisa A Maier, Lori A Kittle, Lee S Newman.   

Abstract

Beryllium (Be) is a lightweight and durable metal useful to a variety of manufacturing processes. With the use of Be in industrial settings, a number of health effects were noted including acute pneumonitis, sensitization to Be, interstitial lung disease and dermatological disease. Interstitial mononuclear cell inflammation and granuloma formation are the primary processes that occur in the lungs of Be-exposed workers, resulting in chronic beryllium disease (CBD). Recent studies have begun to describe the role of Be in the pathogenesis of CBD. These studies reveal that the host's response to Be involves components of the innate immune system or inflammatory responses. Inflammatory responses to Be can establish a state of acquired, Be antigen-specific, cell-mediated immunity. Despite triggering both the innate and acquired immune responses, Be is not eliminated from the host. Rather, it establishes pathways leading to chronic granulomatous inflammation. We will examine recent studies describing the host's cellular and molecular responses to Be, responses that promote granuloma formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11811929     DOI: 10.1016/s1567-5769(01)00177-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  12 in total

Review 1.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

Review 2.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

3.  Conference summary.

Authors:  Philippa Marrack
Journal:  Proc Am Thorac Soc       Date:  2007-08-15

4.  The bioinorganic chemistry and associated immunology of chronic beryllium disease.

Authors:  Brian L Scott; T Mark McCleskey; Anu Chaudhary; Elizabeth Hong-Geller; S Gnanakaran
Journal:  Chem Commun (Camb)       Date:  2008-05-09       Impact factor: 6.222

5.  Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.

Authors:  Mehrdad Arjomandi; James Seward; Michael B Gotway; Stephen Nishimura; George P Fulton; Josef Thundiyil; Talmadge E King; Philip Harber; John R Balmes
Journal:  J Occup Environ Med       Date:  2010-06       Impact factor: 2.162

6.  Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases.

Authors:  Swati Phalke; Katja Aviszus; Kira Rubtsova; Anatoly Rubtsov; Briana Barkes; Linda Powers; Brenda Warner; James L Crooks; John W Kappler; Evans R Fernández-Pérez; Lisa A Maier; Nabeel Hamzeh; Philippa Marrack
Journal:  Am J Respir Crit Care Med       Date:  2020-10-01       Impact factor: 21.405

7.  Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease.

Authors:  Richard T Sawyer; Andrew P Fontenot; Tristan A Barnes; Charles E Parsons; Brian C Tooker; Lisa A Maier; May M Gillespie; E Brigitte Gottschall; Lori Silveira; James Hagman; Lee S Newman
Journal:  Am J Respir Cell Mol Biol       Date:  2006-09-15       Impact factor: 6.914

Review 8.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

9.  Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.

Authors:  Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

Review 10.  A reconsideration of acute Beryllium disease.

Authors:  Kristin J Cummings; Aleksandr B Stefaniak; M Abbas Virji; Kathleen Kreiss
Journal:  Environ Health Perspect       Date:  2009-04-28       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.